Pharsight

Nesina patents expiration

Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(11 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(1 year, 8 months from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble
Jun, 2029

(5 years from now)

Nesina is owned by Takeda Pharms Usa.

Nesina contains Alogliptin Benzoate.

Nesina has a total of 4 drug patents out of which 0 drug patents have expired.

Nesina was authorised for market use on 25 January, 2013.

Nesina is available in tablet;oral dosage forms.

Nesina can be used as method of treating diabetes comprising administering a compound such as alogliptin, method of treating diabetes comprising administering alogliptin.

The generics of Nesina are possible to be released after 16 June, 2029.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage

NESINA family patents

Family Patents